INBX (Inhibrx Biosciences) FCF Margin % : -43,736.00% (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Inhibrx Biosciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Inhibrx Biosciences's Free Cash Flow for the three months ended in Dec. 2024 was $-43.74 Mil. Inhibrx Biosciences's Revenue for the three months ended in Dec. 2024 was $0.10 Mil. Therefore, Inhibrx Biosciences's FCF Margin % for the quarter that ended in Dec. 2024 was -43,736.00%.

As of today, Inhibrx Biosciences's current FCF Yield % is -96.86%.

The historical rank and industry rank for Inhibrx Biosciences's FCF Margin % or its related term are showing as below:

INBX' s FCF Margin % Range Over the Past 10 Years
Min: -98503 Med: -10994.56 Max: -7032.82
Current: -98503

During the past 3 years, the highest FCF Margin % of Inhibrx Biosciences was -7032.82%. The lowest was -98503.00%. And the median was -10994.56%.

INBX's FCF Margin % is ranked worse than
97.73% of 1011 companies
in the Biotechnology industry
Industry Median: -137.96 vs INBX: -98503.00

Inhibrx Biosciences FCF Margin % Historical Data

The historical data trend for Inhibrx Biosciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibrx Biosciences FCF Margin % Chart

Inhibrx Biosciences Annual Data

Trend

Dec22

Dec23

Dec24

FCF Margin %

-7,032.82

-10,994.56

-98,503.00

Inhibrx Biosciences Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial				-3,688.07	-	-81,309.00	-	-43,736.00

Competitive Comparison of Inhibrx Biosciences's FCF Margin %

For the Biotechnology subindustry, Inhibrx Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inhibrx Biosciences's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibrx Biosciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Inhibrx Biosciences's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Inhibrx Biosciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Inhibrx Biosciences's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-197.006	/	0.2
	=	-98,503.00 %

Inhibrx Biosciences's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-43.736	/	0.1
	=	-43,736.00 %

Inhibrx Biosciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Inhibrx Biosciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibrx Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibrx Biosciences Inc (NAS:INBX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

11025 N. Torrey Pines Road, Suite 140, La Jolla, CA, USA, 92037

Website

https://www.inhibrx.com

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.